Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.2%

6 terminated/withdrawn out of 65 trials

Success Rate

87.2%

+0.7% vs industry average

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

27%

11 of 41 completed trials have results

Key Signals

6 recruiting11 with results6 terminated

Enrollment Performance

Analytics

N/A
33(86.8%)
Phase 4
2(5.3%)
Phase 3
2(5.3%)
Phase 2
1(2.6%)
38Total
N/A(33)
Phase 4(2)
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials
NCT07267624Not ApplicableNot Yet Recruiting

EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)

Role: collaborator

NCT07491419Not ApplicableRecruiting

The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)

Role: collaborator

NCT06713642Not ApplicableCompleted

SPOTFIRE Sore Throat (ST) Study

Role: collaborator

NCT05064462Completed

TTV Viral Load in Heart Transplant Recipients

Role: collaborator

NCT07453914Not ApplicableNot Yet Recruiting

Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship

Role: lead

NCT04434209Not ApplicableTerminated

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

Role: lead

NCT06449183Not ApplicableCompleted

VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)

Role: lead

NCT07432113Not ApplicableNot Yet Recruiting

Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.

Role: collaborator

NCT05741424Not ApplicableCompleted

Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU

Role: collaborator

NCT05425251Completed

BRAINI-2 Elderly Mild TBI European Study

Role: collaborator

NCT02638779Not ApplicableCompleted

REAnimation Low Immune Status Markers

Role: collaborator

NCT04392401Recruiting

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study

Role: collaborator

NCT06271655Not ApplicableActive Not Recruiting

Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)

Role: collaborator

NCT03659773Not ApplicableCompleted

Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

Role: collaborator

NCT02668237Not ApplicableCompleted

Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP

Role: collaborator

NCT06174649Not ApplicableCompleted

Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial

Role: collaborator

NCT06829719Not ApplicableRecruiting

TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation

Role: collaborator

NCT05280132Not ApplicableRecruiting

Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial

Role: collaborator

NCT04781530Not ApplicableCompleted

Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms

Role: collaborator

NCT05885529Recruiting

Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries

Role: collaborator